Repositioning Candidate Details
| Candidate ID: | R0011 |
| Source ID: | DB00126 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Ascorbic acid |
| Synonyms: | |
| Molecular Formula: | C6H8O6 |
| SMILES: | [H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO |
| Structure: |
|
| DrugBank Description: | A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. |
| CAS Number: | 50-81-7 |
| Molecular Weight: | 176.1241 |
| DrugBank Indication: | Used to treat vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant. It has also been suggested to be an effective antiviral agent. |
| DrugBank Pharmacology: | Ascorbic Acid (vitamin C) is a water-soluble vitamin indicated for the prevention and treatment of scurvy, as ascorbic acid deficiency results in scurvy. Collagenous structures are primarily affected, and lesions develop in bones and blood vessels. Administration of ascorbic acid completely reverses the symptoms of ascorbic acid deficiency. |
| DrugBank MoA: | In humans, an exogenous source of ascorbic acid is required for collagen formation and tissue repair by acting as a cofactor in the posttranslational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins. Ascorbic acid is reversibly oxidized to dehydroascorbic acid in the body. These two forms of the vitamin are believed to be important in oxidation-reduction reactions. The vitamin is involved in tyrosine metabolism, conversion of folic acid to folinic acid, carbohydrate metabolism, synthesis of lipids and proteins, iron metabolism, resistance to infections, and cellular respiration. |
| Targets: | Hyaluronate lyase; DNA; Xylose isomerase; Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2; Phytanoyl-CoA dioxygenase, peroxisomal; Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3; Gamma-butyrobetaine dioxygenase; Dopamine beta-hydroxylase; Peptidyl-glycine alpha-amidating monooxygenase; Prolyl 3-hydroxylase 1; Prolyl 3-hydroxylase 2; Prolyl 3-hydroxylase 3; Prolyl 4-hydroxylase subunit alpha-1; 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1; 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2; Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2; Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3; Lysine-specific demethylase 5D; Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1; Trimethyllysine dioxygenase, mitochondrial; Transmembrane prolyl 4-hydroxylase; Egl nine homolog 1; Egl nine homolog 2; Egl nine homolog 3 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |